Anti-VEGF therapy: the search for clinical biomarkers (Q37206167)

18 August 2017

1 reference

title

Anti-VEGF therapy: the search for clinical biomarkers (English)

1 reference

18 August 2017

0 references

Raffaele Longo

1

1 reference

18 August 2017

Giampietro Gasparini

series ordinal

2

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

301-314

1 reference

Role of angiogenesis in tumor growth and metastasis

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Fundamental Concepts of the Angiogenic Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Predicting benefit from anti-angiogenic agents in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Angiogenic inhibitors: a new therapeutic strategy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Challenges for patient selection with VEGF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Isolation of putative progenitor endothelial cells for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Imaging angiogenesis: applications and potential for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

MRI for assessing antivascular cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Imaging vascular physiology to monitor cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

New technologies and directed agents for applications of cancer imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

VEGF polymorphisms and survival in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

Expression of vascular endothelial growth factor protein in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.3.301

21 January 2018

Identifiers

DOI

10.1586/14737159.8.3.301

1 reference

release_cgglubgfabh7xhcoit47x2jqpe

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cgglubgfabh7xhcoit47x2jqpe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference